1. An immunotherapy method of treating a human suffering from a disease or disorder, which method comprises the steps of:
(i) constructing a first recombinant expression vector encoding a light chain of a therapeutically effective antibody and constructing a second expression vector encoding a heavy chain of said therapeutically effective antibody;
(ii) introducing said vectors of step (i) into a Chinese hamster ovary (CHO) cell;
(iii) culturing said CHO cell in a culture medium so that said light and heavy chains are produced and a CHO glycosylated therapeutically effective recombinant antibody is thereby produced;
(iv) recovering said therapeutically effective recombinant antibody of step (iii);
(v) administering the recombinant antibody of step (iv) in a therapeutically effective amount to said human.
2. The method of claim 1 wherein the recombinant antibody is a human, chimeric, CDR-grafted or bi-specific antibody.
3. The method of claim 1 wherein the human is afflicted with a T-cell disorder.
4. The method of claim 3 wherein the T-cell disorder is severe vasculitis, rheumatoid arthritis or systemic lupus.
5. The method of claim 1 wherein the human is afflicted with an autoimmune disease.
6. The method of claim 5 wherein the autoimmune disease is multiple sclerosis, graft vs host disease, psoriasis, Juvenile onset diabetes, Sjogrens disease, thyroid disease, myasthenia gravis, transplant rejection or asthma.
7. The method of claim 1 wherein the human is afflicted with cancer.
8. The method of claim 7 wherein the cancer is non-Hodgkins lymphoma or multiple myeloma.
9. The method of claim 1 wherein the human is afflicted with an infectious disease.
10. The method of claim 9 wherein the infectious disease is HIV or herpes.
11. An immunotherapy method of treating a human suffering from a disease or disorder, which method comprises the steps of:
(i) transforming a Chinese hamster ovary (CHO) cell with a recombinant expression vector such that said cell can express a recombinant antibody;
(ii) culturing said CHO cell in serum-free medium so that a CHO glycosylated therapeutically effective recombinant antibody is thereby produced;
(iii) recovering said therapeutically effective recombinant antibody of step (ii);
(iv) administering the recombinant antibody of step (iii) in a therapeutically effective amount to said human.
12. The method of claim 11 wherein the recombinant antibody is a human, chimaeric, CDR-grafted or bi-specific antibody.
13. The method of claim 11 wherein the human is afflicted with a T-cell disorder.
14. The method of claim 13, wherein the T-cell disorder is severe vasculitis, rheumatoid arthritis or systemic lupus.
15. The method of claim 11 wherein the human is afflicted with an autoimmune disease.
16. The method of claim 15 wherein the autoimmune disease is multiple sclerosis, graft vs host disease, psoriasis, Juvenile onset diabetes, Sjogrens disease, thyroid disease, myasthenia gravis, transplant rejection or asthma.
17. The method of claim 11 wherein the human is afflicted with cancer.
18. The method of claim 17 wherein the cancer is non-Hodgkins lymphoma or multiple myeloma.
19. The method of claim 11 wherein the human is afflicted with an infectious disease.
20. The method of claim 19 wherein the infectious disease is HIV or herpes.
21. The method of claim 11 wherein the cell is cultured in said serum-free medium for greater than two months.
22. The method of claim 21 wherein the cell is cultured in said serum free medium for greater than five months.
23. The method of claim 11 wherein the culture undergoes multiple passage.
24. The method of claim 11 wherein the serum free medium comprises water, an osmolarity regulator, a buffer, an energy source, L-glutamine and at least one additional amino acid, an inorganic iron source and a recombinant growth factor wherein each component of said medium is obtained from a source other than directly from an animal source.
25. The medium of claim 11 wherein the medium is devoid of bovine serum albumin, pure human transferrin and soyabean lecithin.
26. The method of claim 11 wherein the growth factor is recombinant insulin.
27. The method of claim 11 wherein the basal medium component of said serum-free medium is an Iscove modification of DMEM.
28. The method of claim 11 wherein the serum-free medium consists essentially of the medium of WCM4.
29. The method of claim 11 wherein the serum-free medium consists essentially of the medium of WCM 5.
30. The method of claim 11 wherein the serium-free medium consists of the medium WCM 4.
31. The method of claim 11 wherein the serum-free medium consists of the medium WCM 5.
32. An immunotherapy method of treating a human suffering from a disease or disorder, which method comprises the steps of:
administering to a human suffering from a disease or disorder, a therapeutically effective amount of a therapeutically effective recombinant human antibody or recombinant altered antibody, said recombinant antibody comprising two light chains and two heavy chains and having an Fc region and a Fab region, wherein said recombinant antibody is expressed in a Chinese hamster ovary (CHO) cell and glycosylated in said Fc region by said CHO cell.
33. The method of claim 32, wherein said antibody has complement lysis activity in an in vitro assay.
34. The method of claim 32, wherein when said antibody is bound to a target cell in said human, the cell to which it is bound is lysed.
35. The method of claim 32, wherein said antibody contains human constant domains.
36. The method of claim 8, wherein the cancer is non-Hodgkins lymphoma.
37. The method of claim 18, wherein the cancer is non-Hodgkins lymphoma.
38. The method of claim 32, wherein the cancer is non-Hodgkins lymphoma.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A folding tool comprising:
a handle defining a track;
an implement pivotably connected to the handle for moving between a closed position and an open position; and
a lock for retaining the implement in the open position, the lock comprising:
a pivotable member configured to pivot relative to the handle between first and second positions; and
an engagement member disposed within the track and configured for movement with the implement through the track, the engagement member also configured to engage the pivotable member upon movement of the implement from the closed position to the open position in order to move the pivotable member from the first position toward the second position;
wherein the pivotable member is configured to return to the first position once the implement is in the open position in order to secure the implement in the open position, and
wherein the pivotable member comprises a cam member configured to pivot about a pivot point, wherein the cam member comprises a curved surface spaced from the pivot point by a distance that increases from a first edge of the cam member to a portion of the cam member spaced from the first edge of the cam member, wherein the engagement member is configured to engage the first edge and the curved surface during movement of the implement from the closed position to the open position, wherein in the first position the pivotable member at least partially overlies the track, and wherein in the second position the pivotable member moves away and is spaced apart from the track so as to no longer overlie the track.
2. A folding tool according to claim 1, wherein opposite ends of the track extend beyond the pivotable member such that movement of the engagement member with the implement between the open and closed positions causes the pivotable member to be displaced from the track into the second position while the implement is in an intermediate position and to permit the pivotable member to return to the first position while the implement is in both the open and closed positions.
3. A folding tool according to claim 1 further comprising a spring for biasing the pivotable member toward the first position.
4. A folding tool according to claim 1 further comprising an actuation member operably connected to the pivotable member and configured to permit manual movement of the pivotable member relative to the handle.
5. A folding tool according to claim 1 further comprising an engagement spring for engaging the engagement member once the implement is in the closed position in order to bias the implement to remain in the closed position.